famotidine
famotidine: 8 clinical trials tracked.
famotidine evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
What is verified about famotidine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 5 study sponsors
Clinical Trials (8)
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986533 in Healthy Participants, an Open-label Assessment of Food and pH Effects on the Relative Bioavailability of BMS-986533, and an Open-label Study to Evaluate P-gp- and BCRP-mediated Drug-Drug Interaction Potential of BMS-986533 in Healthy Participants
Primary endpoint: Number of participants with Adverse Events (AE)
Prevent Allergic Reactions to Aphexda With Dexamethasone (PARADE)
Primary endpoint: Incidence and severity of systemic reactions
An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
Primary endpoint: Pharmacokinetics Parameter (PK): Cmax of INCB161734
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Tolerability of NX-5948 Tablets Following Single and Multiple Ascending Doses, the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, the Effect of NX-5948 on the QT Interval, the Effect of Food on the Pharmacokinetics of NX-5948, Drug-Drug Interactions With NX-5948, and the Intra-Subject Variability of the Bioavailability of NX-5948 Capsules
Primary endpoint: Area under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948
A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470
Primary endpoint: Number of participants with adverse events (AEs)
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Dose-Escalation, Drug-Interaction, and Food-Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participants
Primary endpoint: Number of participants with Treatment Emergent Adverse Events (TEAEs)
A Phase 1 Open-label, 2-Part Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of Afimetoran (BMS-986256) in Healthy Participants
Primary endpoint: Maximum observed plasma concentration (Cmax)
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) to Evaluate the Safety and Efficacy of Drug Combinations in COVID-19 Patients
Primary endpoint: (LDOS-21-001-01) Time-to-event to achieve WHO level ≤3